Inactive Instrument

Jounce Therapeutics, Inc.

Equities

JNCE

US4811161011

Biotechnology & Medical Research

Jounce Therapeutics, Inc. has completed an IPO in the amount of $101.84 million.

January 26, 2017 at 12:00 am

Jounce Therapeutics, Inc. has completed an IPO in the amount of $101.84 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,365,000 PriceRange: $16 Discount Per Security: $1.12 Transaction Features: Reserved Share Offering; Sponsor Backed Offering

Latest news about Jounce Therapeutics, Inc.

Graphite Bio, Inc. Announces Executive Changes	23-08-23	CI
Jounce Therapeutics, Inc. Announces Board Changes	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite Index	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P Global BMI Index	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P TMI Index	23-05-04	CI
Concentra Biosciences, LLC completed the acquisition of Jounce Therapeutics, Inc. from Tang Capital Management, LLC and others.	23-05-02	CI
Redx confirms Jounce deal lapses, Tirupati seals deal	23-04-03	AN
Redx Pharma Shares Fall 5% as Merger With Jounce Therapeutics Fails	23-04-03	MT
Jounce Therapeutics, Inc. Expects Resignation of Elizabeth Trehu as Chief Medical Officer	23-03-30	CI
Sector Update: Health Care Stocks Rise in Late Trading	23-03-27	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-03-27	MT
European Stock Markets Close Higher Monday as First Citizens BancShares' Planned Acquisition of Silicon Valley Bank Assets, Deposits Eases Banking Crisis Fears	23-03-27	MT
Piper Sandler Downgrades Jounce Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.85 From $5	23-03-27	MT
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs	23-03-27	RE
Redx Pharma Says Jounce Therapeutics Terminated Merger Deal; Shares Plunge 19%	23-03-27	MT
Jounce Therapeutics Agrees to be Acquired by Concentra Biosciences	23-03-27	MT
Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer	23-03-27	AN
Jounce Therapeutics, Inc. completed the acquisition of Redx Pharma Plc from a group of sellers and other shareholders.	23-03-26	CI
Jounce Therapeutics, Inc. Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer	23-03-16	CI
Sector Update: Health Care Stocks' Late Recovery Stalls	23-03-15	MT
Sector Update: Health Care Stocks Moderately Lower	23-03-15	MT
Top Midday Gainers	23-03-15	MT
Sector Update: Health Care Stocks Retreat Pre-Bell Wednesday	23-03-15	MT
Redx Pharma Says Merger Target Jounce Therapeutics Received New Takeover Proposal; Stock Surges 34%	23-03-15	MT
Sector Update: Health Care	23-03-15	MT

Chart Jounce Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). It also develops JTX-1484 and JTX-2134 product candidates.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+23.26%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-15.13%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs